EUCTR2016-005122-11-DE进行中（未招募）1 期
A multicenter, open label, single-arm pilot to evaluate the efficacy and safety of oral apremilast in patients with moderate to severe palmoplantar pustulosis (PPP) (APLANTUS) - APLANTUS
Prof. Dr. Kristian Reich0 个研究点目标入组 20 人开始时间: 2017年11月21日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Male and female patients aged 18 years or more at screening visit.
- •-Patients with chronic PPP (disease history of at least 6 months of diagnosis), who
- •are eligible for treatment with systemic therapy defined as having PPP
- •inadequately controlled by topical treatment and / or phototherapy and / or
- •previous systemic therapy
- •-Patients with chronic moderate to severe PPP defined as patients with a PPPASI
- •= 12 with or without concomitant plaque-type psoriasis
- •-Negative result of a urine pregnancy test taken at screening and at baseline for
- •all women, except those who are surgically sterile or at least 1 year postmenopausal (i.e. at least 12 consecutive months with amenorrhea without other known or suspected medical cause).
- •- Willingness and capability of using highly effective contraceptive measures from Screeing visit until the end of at least one menstrual cycle (but not less than 28 days) following discontinuation of apremilast as defined below:
- •- Females patient of childbearing potential (fertile, following menarche and until becoming post-menopausal unless permanently sterile) using a highly effective method of contraception OR female patients of non-childbearing potential (surgically sterilized [e.g. hysterectomy, bilateral salpingectomy and bilateral oophorectomy] or post-menopausal)
- •- Male patient, and his female partner of childbearing potential, using a highly effective method of contraception
- •- Adequate contraceptive method defined as:
- •A method with less than 1% failure rate (e.g. permanent sterilization, hormone implants, hormone injections, some intrauterine devices, or vasectomized partner)
- •The use of two methods of contraception (e.g. one barrier method [condom, diaphragm or cervical/vault caps] with spermicide and one hormonal contraceptive [e.g. combined oral contraceptives, patch, vaginal ring, injectables and implants])
- •- Patient is capable of understanding and giving written, voluntary informed consent before study screening.
- •- Willingness and capability of complying with all study procedure requirements, as per the Investigator’s judgment (e.g. patient able to swallow the apremilast tablets, blood sampling).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 20
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •-Pregnant or breast-feeding women.
- •-Current or history of psychiatric disease that would interfere with the ability to comply
- •with the study protocol or give informed consent.
- •-Patients known to have had a substance abuse (drug or alcohol) problem within the previous 12 month
- •-Individuals who are involved in the organization of the study
- •-Patients who are in any way dependent on the investigator
- •-Patients who are participating in a clinical study
- •-Relatives, partner or staff of any clinical site personnel
- •Disease-related
- •-Evidence of skin conditions (e.g. eczema) other than PPP / psoriasis that would
- •interfere with evaluations of the effect of study medication on PPP or psoriasis.
- •-Laboratory values from routine blood test taken within the 8 weeks prior to
- •screening with any of the following:
- •-Serum creatinine >1.4 x upper limit of normal (ULN) for age and gender
- •- Estimated Glomerular Filtration Rate (eGFR) < 30 mL/min/1.73 m2 according to the CKD-EPI equation
- •-Pustular psoriasis lesions on the part of body other than hands or feet
- •-Significant concurrent medical conditions at the time of screening, including:
- •*Risk factors for renal toxicity (renal inflammation)
- •*Severe hepatic dysfunction
- •*Unstable angina pectoris
- •*Uncompensated congestive heart failure
- •*Severe pulmonary disease requiring hospitalization or supplemental oxygen
- •*Immunodeficiency disorders: primary or secondary
- •*Known positive HIV test result, hepatitis B surface (HBS) antigen or hepatitis
- •C (HCV) test result
- •*Uncontrolled Insulin-dependent diabetes mellitus
- •*Cancer or history of cancer (except for resected cutaneous basal cell or
- •squamous cell carcinoma) in the last 5 years
- •*Open cutaneous ulcers
- •-Any condition that, in the judgment of the investigator, might cause this study to be
- •detrimental to the patient.
- •Medication-related
- •-Ultraviolet B (UVB) therapy, topical steroids, topical calcineurin inhibitors, topical
- •Vitamin A or D analog preparations, or anthralin within 14 days of baseline
- •Exceptions: low potency topical corticosteroids (class I and II, according to European
- •classification for potency of topical corticosteroids) will be allowed as therapy for the
- •face, groin, axillae in accordance with the manufacturer’s suggested usage dose
- •-Psoralen plus ultraviolet A radiation (PUVA), ciclosporin, acitretin, alitretinoin, alefacept
- •(Amevive®), anakinra (Kineret®), systemic corticosteroids, methotrexate, fumaric acids
- •or any other systemic anti-psoriasis therapy within 28 days of baseline
- •-Prior (within the last 2 years) or concomitant use of antipsoriatic biologic therapy with
- •TNF-alpha blocker and / or ustekinumab and / or ixekizumab and / or secukinumab
- •and / or brodalumab and / or guselkumab
- •-Concomitant use of strong cytochrome P450 3A4 (CYP3A4) enzyme inductors (e.g.
- •rifampicin, phenobarbital, carbamazepin, phenytoin and St. John`s wort)
- •-Use of an investigational drug within 4 weeks prior to baseline or 5 pharmacokinetic /
- •pharmacodynamics half-lives (whichever is longer)
- •-Prior treatment with apremilast / Otezla®
- •-Receipt of any live (attenuated) vaccine within 28 days prior to baseline
- •-Concomitant use of any other PDE4 inhibitor
- 另有 4 项未显示
研究者
相似试验
进行中（未招募）
1 期
A multicenter, open label, single-arm pilot study to evaluate the efficacy and safety of guselkumab in patients with moderate to severe palmoplantar pustulosis (PPP)EUCTR2018-004451-20-DERheinische Friedrich-Wilhelms-Universität Bonn50
招募中
Unknown
Transcatheter Arterial Micro-Embolization (TAME) using Nexsphere-F in Patients with Chronic Pain in Elbow or WristDiseases of the musculoskeletal system and connective tissueKCT0009270Konkuk University Medical Center38
进行中（未招募）
不适用
An open-label, prospective, multicentric pilot study evaluating safety and symptomatics effects of low dose Naltrexone in patients with primary progressive multiple sclerosis. - NDMedDRA version: 6.1Level: PTClassification code 10053395multiple sclerosisEUCTR2005-005679-13-ITOSPEDALE S. RAFFAELE40
尚未招募
Unknown
Early detection of oral cancer by ERLY SIGN Kit by using saliva sample.CTRI/2024/07/069769CURO Biosciences Private Limited
已完成
4 期
Effectiveness of Restylane® used for treatment of facial wrinkles, facial folds, volume loss and lips augmentation.CTRI/2017/09/009848Galderma India Pvt Ltd100